CN101301299A - Medicament composition and use thereof in preparing antimicrobial medicament - Google Patents
Medicament composition and use thereof in preparing antimicrobial medicament Download PDFInfo
- Publication number
- CN101301299A CN101301299A CNA2007100279999A CN200710027999A CN101301299A CN 101301299 A CN101301299 A CN 101301299A CN A2007100279999 A CNA2007100279999 A CN A2007100279999A CN 200710027999 A CN200710027999 A CN 200710027999A CN 101301299 A CN101301299 A CN 101301299A
- Authority
- CN
- China
- Prior art keywords
- triclosan
- salt
- acid
- tannic acid
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 230000000845 anti-microbial effect Effects 0.000 title description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 91
- 229920002258 tannic acid Polymers 0.000 claims abstract description 77
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 76
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 76
- 229940033123 tannic acid Drugs 0.000 claims abstract description 76
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 76
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims abstract description 59
- 229960003500 triclosan Drugs 0.000 claims abstract description 59
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 39
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 37
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 37
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 37
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 206010000496 acne Diseases 0.000 claims abstract description 23
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 19
- 201000010153 skin papilloma Diseases 0.000 claims abstract description 16
- 208000000260 Warts Diseases 0.000 claims abstract description 13
- 241000934136 Verruca Species 0.000 claims abstract description 12
- 241001465754 Metazoa Species 0.000 claims abstract description 9
- 230000003628 erosive effect Effects 0.000 claims abstract description 8
- 208000015181 infectious disease Diseases 0.000 claims abstract description 8
- 241000282414 Homo sapiens Species 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 6
- 230000009385 viral infection Effects 0.000 claims abstract description 6
- 206010008323 cervicitis Diseases 0.000 claims abstract description 5
- 208000006374 Uterine Cervicitis Diseases 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 23
- 241000701806 Human papillomavirus Species 0.000 claims description 20
- 210000004877 mucosa Anatomy 0.000 claims description 17
- 230000000844 anti-bacterial effect Effects 0.000 claims description 15
- 206010059313 Anogenital warts Diseases 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 12
- 241000233866 Fungi Species 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 241000222122 Candida albicans Species 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 241000282412 Homo Species 0.000 claims description 8
- 229940095731 candida albicans Drugs 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims 2
- 208000031888 Mycoses Diseases 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 208000021145 human papilloma virus infection Diseases 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 230000000474 nursing effect Effects 0.000 claims 1
- 239000002453 shampoo Substances 0.000 claims 1
- 239000000606 toothpaste Substances 0.000 claims 1
- 229940034610 toothpaste Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 24
- 239000000645 desinfectant Substances 0.000 abstract description 23
- 229940079593 drug Drugs 0.000 abstract description 11
- 208000001688 Herpes Genitalis Diseases 0.000 abstract description 6
- 208000007514 Herpes zoster Diseases 0.000 abstract description 6
- 201000004946 genital herpes Diseases 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 5
- 241000894006 Bacteria Species 0.000 abstract description 4
- 210000004400 mucous membrane Anatomy 0.000 abstract description 4
- 208000009889 Herpes Simplex Diseases 0.000 abstract description 2
- 206010046914 Vaginal infection Diseases 0.000 abstract description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 abstract 2
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 62
- 239000002253 acid Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 241000700605 Viruses Species 0.000 description 15
- 238000002156 mixing Methods 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229960004150 aciclovir Drugs 0.000 description 6
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- 208000004898 Herpes Labialis Diseases 0.000 description 5
- 206010067152 Oral herpes Diseases 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 description 5
- 206010037888 Rash pustular Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 208000029561 pustule Diseases 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 3
- 241000341655 Human papillomavirus type 16 Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000032420 Latent Infection Diseases 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000004196 common wart Diseases 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009854 mucosal lesion Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-UHFFFAOYSA-N 2-(3,4-Dihydroxyoxolan-2-yl)-2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)C1OCC(O)C1O HVUMOYIDDBPOLL-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010062317 Condyloma latum Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 244000110343 Elephantopus scaber Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001063 anti-aarboviral effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 201000003988 chronic cervicitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- VRSMJNVXOITYPE-FSDIUQKZSA-N ethyl 4-[[(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VRSMJNVXOITYPE-FSDIUQKZSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000008121 plant development Effects 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 210000002222 superior cervical ganglion Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an application of glycyrrhizic acid or a compound of a salt thereof and tannic acid and triclosan in the preparation of anti skin mucous membrane microorganism and acne drugs, in particular to the application in the preparation of drugs for preventing and treating bacteria, mycotic and virus infections of skin mucous membranes of human beings and animals, acne drugs, disinfectant and daily chemical products, wherein, the infections comprise verruca acuminate, verruca plana, common warts, colpitis, cervicitis, cervical erosion, herpes simplex, herpes zoster, herpes genitalis and aece. The application is to blend the glycyrrhizic acid or the compound of the salt thereof and the tannic acid and the riclosan with various auxiliary materials of skin mucous membrane dosage and prepare the mixture into different preparations.
Description
Technical field
The present invention relates to the application of compositions in anti-skin mucosa microorganism of preparation and acne medicine of glycyrrhizic acid or its salt, tannic acid and triclosan.The compositions that relates to glycyrrhizic acid or its salt, tannic acid and triclosan specifically is used to prepare the application of treatment humans and animals skin mucosa antibacterial, fungus, viral infection and acne medicine, disinfectant and daily chemical product.
Background technology
Glycyrrhizic acid or its salt have the nonspecific immunity regulating action, it mainly strengthens cellular immunization, can strengthen phagocytic function, optionally strengthen the multiplication capacity and the activity of helper T cell, have antimicrobial, protect the liver, various biological effect such as detoxifcation, antiinflammatory, antiallergic action, antiallergic.Carry out external anti-Epstein-Barr virus experiment [Jung-Chung Lin.Mechanism of action ofglycyrrhizic acid in inhibition of Epstein-Barr virus replication invitro[J] .Antiviral Res with glycyrrhizic acid, 2003,59:41-47], find duplicating in early days of glycyrrhizic acid viral interference, but do not influence the absorption of virus, can not make the virus particle inactivation yet; Experiment in vitro also shows, glycyrrhizic acid has anti-arboviral effect [Jean MC, Natale S, Alain J, et al.Interferon, ribavirin, 6-azauridine and glycyrrhizin:antiviral compounds activeagainst pathogenic flavivi-ruses[J] .Antiviral Res, 2003,58:73-79].
Tannic acid is as astringency, and existing on the market tannic acid ointment is used for neonate and baby, and to prevent and treat buttocks red.Tannic acid has been proved to be to be had inhibitory action to acquired immune deficiency syndrome (AIDS) HIV virus (Biochem.J 1992; 288:717-9; J.Nat.Prod.1990; 53:134-40).
Triclosan is the highly effective and safe antibiosis and sterilization agent, can kill multiple gram positive bacteria, negative bacterium and funguses such as staphylococcus aureus, escherichia coli and Candida albicans, virus is also had suppress and killing action.
Skin and mucosa infection antibacterial, fungus and viral micro-organisms are commonly encountered diseases, frequently-occurring disease, and at present many antibiotic therapies of use still usually cause drug resistance, make that skin and mucosa infection is prolonged does not heal.In addition, contacting with human body surface and carry antibacterial, fungus and virus, is the important channel of infectious disease transmission, by killing the pathogenic microbes of skin mucosa, is the important method of such disease of prevention.
Acne claims acne of youth again, is a kind of pilosebaceous chronic inflammatory disease, and good sending out in face, thoracic dorsal shows as infringements such as acne, pimple, pustule, tuberosity, cyst, is more common in youth of both sexes.Majority thinks that microorganism is closely related in primary disease and androgen, sebaceous gland and the hair follicle.In addition, heredity, diet, gastrointestinal function, environmental factors, cosmetics and Nervous and Mental Factors are also relevant with the morbidity of primary disease.
Herpesvirus has I type and I I type, infects zones of different, can be divided into herpes labialis, varicella-zoster, genital herpes etc., and virus can show as proliferative and infect and latent infection.The gene expression of virus is suppressed when infection is in latency, infects and can transfer proliferative under some stimulating factor effect.Hide and recurrent infection be the outstanding feature of herpesvirus.Virus lays dormant is in trigeminal ganglion, superior cervical ganglion and vagus ganglion, impaired as the host neuraxon of latent infection, generate heat or when being subjected to wound (as intubate etc.), ultraviolet radiation etc. and stimulating, virus can be activated and along the nerve fiber axon to tip, thereby entering innerv skin and mucosa breeds again, cause pathological change once again, cause the recurrence of local herpes.
Condyloma acuminatum, verruca vulgaris, verruca plana are the skin mucosal lesionss that is caused by human papillomavirus (HPV).
The traditional Chinese medical science thinks that the etiology and pathogenesis of condyloma acuminatum is owing to the product that sexual life is unclean or mediate contact is filthy, and damp and hot excessive poison is cloudy mucocutaneous from outer intrusion, causes the strongly fragrant gesture of Liver Channel, disharmony between QI and blood, and damp and hot malicious heresy is fought to tie and is formed wart.Because noxious dampness is a YIN pathogen, its property viscous, touching difficulty is gone, and consumption is hindered healthy energy easily, and deficient vital QI leading to lingering of pathogen so that recurrence easily are difficult to radical cure.The methods such as strengthening the body resistance, heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, hard masses softening and resolving that adopt in treatment more.Condyloma acuminatum is based on local patholoic change, so external treatment accounts for critical role in treatment.U.S. Pat 4381296 discloses tannic acid and has been used for the treatment that herpesvirus HSV infects, but does not relate to the treatment of condyloma acuminatum HPV.At present, the medicine of treatment condyloma acuminatum has podophyllotoxin d, belongs to chemotherapy, and advantage is a short treating period, but has zest, problem that toxic and side effects is big.Concrete manifestation is pain, edema, erosion etc.
At present, existing product on the market, as acyclovir, the treatment herpes labialis takes effect slowly, often needs just recovery from illness of a week, and verruca plana adopts naturopathy means such as laser, cryotherapy more, lacks effective medicine.
Simultaneously can antibacterium, fungus, viral various skin mucosa infected by microbes, the double preparation of controlling acne is not being seen on the market with on the document as yet.The usually not clear cause of disease of skin mucosal lesions or mixed infection, acne is usually with skin infection or allergy, it is the cureless reason of many skin infections or acne, lack very much wide spectrum, efficient, low toxicity clinically, to the effective pharmaceutical preparation of drug-resistant microorganism, developing this class preparation is the anti-infectives research direction.
Summary of the invention
The present invention is that the compositions of glycyrrhizic acid or its salt, tannic acid and triclosan is as active component.
Glycyrrhizic acid extracts from Radix Glycyrrhizae, uses glycyrrhizic acid or its salt, as tripotassium glycyrrhetate, diammonium glycyrrhizinate.Also can be from buying on the market.
Tannic acid is called tannin again, tannin, and tannin is the class material that molecular weight varies in size, macromole tannic acid degradable is the micromolecule tannic acid, also can obtain by synthetic.Tannic acid can be extracted by various plants, and is first-selected from Galla Chinensis, Fructus rhois chinensis, Pericarpium Granati and banana stalk extraction, the tannic acid that preferred molecular weight is little.
Triclosan has another name called triclosan, and 2,4,4 '-three chloro-2 '-dihydroxy diphenyl ethers are added to disinfectant or daily chemical product and are used for pressing down antibacterial, fungus and virus extremely, can be from buying on the market.
Glycyrrhizic acid and salt thereof, tannic acid and triclosan compositions by a certain percentage, wherein glycyrrhizic acid or its salt are the 1-50 weight portion, tannic acid is the 1-100 weight portion, triclosan is the 1-30 weight portion, being preferably glycyrrhizic acid or its salt is the 1-30 weight portion, and tannic acid is the 10-90 weight portion, and triclosan is the 1-5 weight portion.
In recent years result of study shows (Chen Fuqiang etc., treatment and prevention of tumour magazine, 2001,8 (4) 342-344; Xu Chengkang, Zhongshan Medical Univ.'s journal, 1998,19 (3): 223-226), 29.3% the patients of cervical ruin HPV positive, and the normal cervix positive rate only is 11.1%.It is reported (Ahn ws et al, J Cell BiochemSuppl, 1997; 28-29:133-139), high-risk HPV (16,18) type expression rate is 69% in the chronic cervicitis.HPV is relevant with multiple disease, it is divided into many hypotypes, according to it to organizing the size of vicious transformation degree, HPV is divided into high, medium and low danger type, wherein high-risk-type comprises HPV16,18, HPV16 is modal hypotype in cervical erosion and the cervical cancer, high-risk HPV 16,18 recall rates present with the increase of the rotten to the corn degree of official's neck and increase progressively trend, granular pattern or papillary erosion HPV16,18 recall rates and normal cervix comparing difference are remarkable, show that cervical cancer and HPV are closely related, closely related with cervical erosion.Can record with PCR in the cervical cancer of 85%-90% high-risk HPV is arranged, HPV16,18 positive rates reach 83.33% in the cervical cancer, high-risk HPV DNA is incorporated into host cell chromosome, can produce E6, E7 oncoprotein, they suppress antioncogene p53 and Rb respectively, make cell escape the control of p53 and Rb, cause cell cycle control not normal, make active, the tumor growth of the hyperplasia that remains static usually.Infect though there is the main trafficability characteristic of most childbearing age women to propagate, have only minority to develop into cervical cancer,, just can make the cervical lesions progress if HPV16 continues to exist.Cervical HPV infection and pudendum infect different, based on the HPV16/18 type, condyloma latum does not often take place change, but with the inapparent infection long-term existence, cause atypical hyperplasia earlier in the palace, when other factors participate in and cause canceration.HPV6/11,16/18 type can be killed and suppress to the compositions of above-mentioned glycyrrhizic acid or its salt, tannic acid and triclosan effectively, can be used for preparing treatment HPV viral infection and medicine, treatment condyloma acuminatum, verruca plana, verruca vulgaris, vagina, cervicitis and cervical erosion.
The present invention observes active component and product effect by the change that real-time fluorescence quantitative PCR detects the amount of HPV virus, and this method is used (Cai Youling etc., Chinese std aids control, 2002,8:2,108 in the several pieces of documents of publishing; Wu Yuansheng, model are auspicious strong etc., and the practical combination of Chinese and Western medicine is clinical, and 2003,3:2,1).
The result shows, the tissue homogenate of condyloma acuminatum after the compositions that adds glycyrrhizic acid or its salt, tannic acid and triclosan 24 hours, FQ-POVR can not detect virus again, and blank pipe and contrast QC have the very HPV virus quantity of high concentration, illustrate that medicine of the present invention and effective ingredient thereof have the ability of the HPV virus of fast and effeciently going out.
Experiment showed, that independent use tannic acid medicinal liquid has inhibition to staphylococcus aureus, escherichia coli and bacillus pyocyaneus, but Candida albicans is not had bacteriostasis.The compositions of glycyrrhizic acid of the present invention or its salt, tannic acid and triclosan then all has inhibition to staphylococcus aureus, escherichia coli, bacillus pyocyaneus and Candida albicans.
The compositions of glycyrrhizic acid of the present invention or its salt, tannic acid and triclosan can prevent and treat the purposes of humans and animals skin mucosa antibacterial, fungus, viral disease and acne medicine simultaneously in preparation, comprise acne, herpes simplex, genital herpes, varicella-zoster, condyloma acuminatum, verruca plana, bacillary, mycotic, viral vaginitis, cervicitis and cervical erosion, particularly treat the purposes of humans and animals skin mucous membrane virus disease medicament.Compositions of the present invention is non-stimulated to skin mucosa, and toxic and side effects is low, and the kind of treatment skin and mucosa infection disease is many, and effect is obvious, and treatment condyloma acuminatum, the about 4-5 of verruca plana days begin progressively to come off.Treatment herpes labialis, herpes zoster, the about 2-3 of genital herpes days incrustation.
The compositions of glycyrrhizic acid of the present invention or its salt, tannic acid and triclosan and contain compositions as glycyrrhizic acid or its salt, tannic acid and the triclosan of active component effective dose, with the application of various supplementary product compatibilities in the various preparations of preparation of skin mucosa medication, can be unguentum, gel, lotion, tablet, suppository, membrane, spray.Can be used for preparing medicine or the disinfectant or the hygienic article of treatment humans and animals skin mucosa antibacterial, fungus, viral infection and acne.
The solids content of the compositions of glycyrrhizic acid or its salt, tannic acid and triclosan is 1-70% in the preparation, is preferably 2-20%.
When being used to prepare pharmaceutical formulation, can make up with different medicine and acceptable carriers, be beneficial to the formation of preparation, in addition, can also add various adjuvants, as surfactant, stabilizing agent, antioxidant, antiseptic and Percutaneous absorption enhancer etc.These carriers and adjuvant can be:
Starch, dextrin, tween 80, carbomer, cellulose, sodium carboxymethyl cellulose, sodium alginate, glycerol, propylene glycol, Polyethylene Glycol, laurocapram, isopropyl alcohol, triethanolamine, sorbester p18, but be not limited thereto.
The pH of the composite preparation of glycyrrhizic acid of the present invention or its salt, tannic acid and triclosan is 1-7, is preferably pH4-6.5.Regulate pH and can use HCl, sulphuric acid, lactic acid, NaOH or KCl.
Below in conjunction with embodiment, further specify the present invention, but the present invention is not limited to these embodiment, any on essence spirit of the present invention improvement or substitute, still belong to desired protection domain in claims of the present invention.
The specific embodiment
Test raw material and medicine source
Glycyrrhizic acid Shaanxi plant development corporation, Ltd. of favour section
Tripotassium glycyrrhetate Gansu Jin Hanbai pharmaceutcal corporation, Ltd
The high biological medicine Science and Technology Ltd. of containing in diammonium glycyrrhizinate Shaanxi
The high biological medicine Science and Technology Ltd. of containing in tannic acid Shaanxi
Triclosan HuBei Hengri Chemical Industry Co.,Ltd.
FUYANJING JIAONANG content (this product is the capsules of flavour of a drug through being processed into such as Radix Picriae felterrae, Elephantopus scaber L., Radix Angelicae Sinensis, Caulis Spatholobi, Radix Zanthoxyli) Guangxi Wuzhou Pharmaceutical Group Plc
Embodiment 1
The preparation of the anti-HPV virus of the compositions of compound glycyrrbizic acid diammonium, tannic acid and triclosan effervescent tablet:
Diammonium glycyrrhizinate 0.20 gram
Tannic acid 1.00 grams
Triclosan 0.10 gram
Tartaric acid 0.45 gram
Sodium bicarbonate 0.65 gram
Dextrin 0.02 gram
PEG6000 0.01 gram
Preparation method: extracting liquorice acid diammonium, tannic acid, triclosan, tartaric acid are crossed 80 mesh sieves respectively, make soft material with 95% ethanol, and the wet grain of the 12 mesh sieve systems of crossing is in 50 ℃ of dryings, standby.Other gets sodium bicarbonate and adds sterile distilled water system soft material, and the wet grain of the 12 mesh sieve systems of crossing in 50 ℃ of dryings, mixes with above-mentioned dry granular then, and granulate adds an amount of sterile purified water, and baking adds PEG6000, dextrin for a moment.Mixing, tabletting.
Embodiment 2
The preparation of compound glycyrrbizic acid tripotassium, tannic acid and triclosan disinfectant solution:
Tripotassium glycyrrhetate 0.10 gram
Tannic acid 5.00 grams
Triclosan 0.30 gram
1,20 milliliters of 2-propylene glycol
20 milliliters of tween 80s
3 milliliters of azones
HCl or NaOH regulate pH to 5.5
Sterile purified water adds to 100 milliliters
Embodiment 3
The preparation of compound glycyrrbizic acid, tannic acid and triclosan disinfectant solution:
Glycyrrhizic acid 1.00 grams
Tannic acid 5.00 grams
Triclosan 0.50 gram
1,15 milliliters of 2-propylene glycol
15 milliliters of tween 80s
3 milliliters of azones
HCl or NaOH regulate pH to 5.5
Sterile purified water adds to 100 milliliters
Embodiment 4
The preparation of compound glycyrrbizic acid diammonium, tannic acid and triclosan gel:
Diammonium glycyrrhizinate 5.00 grams
Tannic acid 30.00 grams
Triclosan 3.00 grams
Carbomer 10 grams
Glycerol 100 grams
Sterile purified water adds to 1000 milliliters
Preparation method: get the carbomer gradation and be sprinkled in an amount of sterile purified water, make its slow swelling, after adding glycerol is mixed well, drip triethanolamine and stir into residuite, pH transfers to 6.0-6.5.Measure diammonium glycyrrhizinate 5.0 gram, tannic acid 30.0 grams, triclosan 3.00 grams, add in an amount of heat sterilization distilled water, after the dissolving cooling, stir while adding again in gel-type vehicle, add sterile purified water to 1000 milliliter at last, stir evenly packing and get final product.
Embodiment 5
Fluorescence quantitative PCR detection HPV virus drug sensitive experiment
The drug sample preparation:
No. 1: tannic acid 5 gram adds 50 milliliters of dissolvings of distilled water, adds 1 again, and each 20 milliliters of 2-propylene glycol, tween 80s add sterile purified water to 100 milliliter at last, are mixed with 5% solution.
No. 2: (compound glycyrrbizic acid tripotassium, tannic acid and triclosan disinfectant solution) presses the disinfectant solution of embodiment 2 preparations
No. 3: FUYANJING JIAONANG content 5 grams, add 1,20 milliliters of 2-propylene glycol, 20 milliliters of tween 80s add sterile purified water to 100 at last, are mixed with 5% solution.
The HPV viral source:
From the condyloma acuminatum specimen of multidigit patients clinical standard, after cutting,, under aseptic condition, specimen is shredded with normal saline flush away blood, add 3 times of volume normal saline mixings, to grind to form homogenate standby.Key instrument:
PE7700 type quantitative real time PCR Instrument (comprising computer and software).
Primer and fluorescent probe:
Reach the HPV6 that peace gene clinical diagnosis center provides, 11 and 16,18 type FQ-PCR diagnostic kits.
Test method
Get condyloma acuminatum tissue homogenate 50 microlitres, add various testing sample 50 microlitres respectively by setting grouping.
37 ℃ of incubations 24 hours, by reaching peace gene diagnosis center HPV6, the operating procedure that 11 and 16,18 type FQ-PCR diagnostic kits provide detects then:
FQ-PCR reactions steps: adopt conventional alkaline lysis method of extracting DNA0.2ml to go in the thin-walled reaction tube, add certain density primer, F-PROBE, DNTP, archaeal dna polymerase and buffer etc. simultaneously, with PE7700 fluorescent PCR instrument, after 93 ℃ of 2min give degeneration, by 93 ℃ of 45s, 55 ℃ of 120s carry out 40 circulations repeatedly, and quantitative result is calculated the quantitative result of initial copy number by the computer software automatic analyser.
Virus HPV 6/11 HPVl6/18
The pipe number (copy/ml) (copy/ml)
Blank pipe 1.45 * 10
61.40 * 10
5
No. 1: tannic acid 00
No. 2: 00
(the compound glycyrrbizic acid tripotassium,
Tannic acid and triclosan disinfectant solution)
No. 3: 3.40 * 10
52.30 * l0
4
(property management of FUYANJING JIAONANG content)
The tissue homogenate of condyloma acuminatum is adding tannic acid respectively, behind compound glycyrrbizic acid tripotassium, tannic acid and the triclosan disinfectant solution 24 hours, FQ-POVR can not detect virus again, and and blank pipe and FUYANJING JIAONANG content pipe have the very HPV virus quantity of high concentration, illustrate that compound glycyrrbizic acid tripotassium of the present invention, tannic acid and triclosan disinfectant solution and tannic acid all have the effect that can fast and effeciently kill condyloma acuminatum virus.
Embodiment 6
Antibacterial and fungal drug sensitive experiment
Extracorporeal bacteria inhibitor test
Experiment material:
Bacterial strain: staphylococcus aureus, escherichia coli, bacillus pyocyaneus and Candida albicans.Reagent: nutrient broth medium, nutrient agar, sabouraud's agar.
The drug sample preparation:
Original liquid preparation: weighing tannic acid 5 grams add sterile purified waters to 100 milliliter respectively, get 0.1 milliliter for the tannic acid original liquid with get compound glycyrrbizic acid tripotassium, tannic acid and triclosan disinfectant solution and be compound glycyrrbizic acid tripotassium, tannic acid and triclosan disinfectant solution original liquid for 0.1 milliliter.
1. get stock solution 2ml as concentration 1.
2. get stock solution 2ml+ distilled water 2ml, mixing takes out 2ml as concentration 2.
3. get 2. in the operation medicinal liquid 2ml+ distilled water 2ml behind the mixing, mixing takes out 2ml as concentration 3.
4. get 3. in the operation medicinal liquid 2ml+ distilled water 2ml behind the mixing, mixing takes out 2ml as concentration 4.
5. get 4. in the operation medicinal liquid 2ml+ distilled water 2ml behind the mixing, mixing takes out 2ml as concentration 5.
6. get 5. in the operation medicinal liquid 2ml+ distilled water 2ml behind the mixing, mixing takes out 2ml as concentration 6.
Experimental technique
Adopt the plate doubling dilution, the medicinal liquid that has prepared is added respectively in the bactericidal nurishing agar culture medium that is cooled to about 55 ℃, mixing is made the medicine flat board of variable concentrations.
The yellow staphylococcus of depletion, escherichia coli, bacillus pyocyaneus, four kinds of experimental bacteria suspensions of Candida albicans, draw respectively and plant in the pastille flat board of variable concentrations, get four flat boards that do not contain medicinal liquid in addition again and also inoculate four kinds of antibacterials), cultivate 18h, observed and recorded minimal inhibitory concentration MIC for 37 ℃.
The tannic acid medicinal liquid the results are shown in following table 1:
Compound glycyrrbizic acid tripotassium, tannic acid and triclosan disinfectant solution the results are shown in following table 2:
Experimental result
1, the tannic acid group all has in various degree inhibitory action (seeing the following form) to 3 kinds of antibacterials (staphylococcus aureus, escherichia coli, bacillus pyocyaneus) of experiment.But to the Candida albicans unrestraint.
The antibacterial action of table 1 tannic acid
2, compound glycyrrbizic acid tripotassium, tannic acid and triclosan disinfectant solution all have in various degree inhibitory action (seeing the following form) to 4 kinds of antibacterials (staphylococcus aureus, escherichia coli, bacillus pyocyaneus, Candida albicans) of experiment.
The antibacterial action of table 2 compound glycyrrbizic acid tripotassium, tannic acid, triclosan disinfectant solution
Embodiment 7
The test of external curing human body skin herpesvirus infection
The various herpesvirus infections of external curing, incrustation is produce effects in 3 days, is effectively in 5 days, 6 days is invalid later on.
Herpes labialis:
22 person-times of herpes labialises are divided into external acyclovir ointment group and compound glycyrrbizic acid tripotassium, tannic acid and triclosan disinfectant solution group at random, every group 11 people, 10 person-times of compound glycyrrbizic acid tripotassium, tannic acid and triclosan disinfectant solution group produce effects, effective 1 people; And 1 person-time of acyclovir ointment group produce effects, effective 4 person-times, invalid 6 person-times, both have significant differences.
Herpes zoster:
Herpes zoster 6 people, compound glycyrrbizic acid tripotassium, tannic acid and triclosan disinfectant solution group 3 people all are produce effects.1 people is effective for the acyclovir ointment group, and 2 people are invalid, use compound glycyrrbizic acid tripotassium, tannic acid and triclosan disinfectant solution instead after, second or three day the incrustation.
Genital herpes
Genital herpes 5 people, all through long-term external acyclovir, imiquimod or take the acyclovir medicine simultaneously, all invalid.Recovery from illness in 3-5 days behind externally used compound tripotassium glycyrrhetate, tannic acid, triclosan disinfectant solution.
Proof compound glycyrrbizic acid tripotassium, tannic acid and triclosan all have the characteristics of instant effect to I and II type herpesvirus infection.
Embodiment 8
The test of treatment human body skin acne
Male 16-30 year 8 people, women 16-30 year 6 people, acne is shown effect repeatedly, inflammatory pimple, pustule, tuberosity, abscess and cicatrix etc. are arranged, wherein male 4 people, women 2 people, through compound glycyrrbizic acid tripotassium, tannic acid and the treatment of triclosan disinfectant solution, all inflammation such as the pimple of case, pustule, abscess disappeared at 2-3 days.And 8 people's externals Viaminate emulsifiable paste is o.3% in addition taken antibiotic simultaneously, inflammation such as pimple, pustule, abscess 2 people of disappearing at 2-3 days, 3 people of disappearing in 5 days, 3 people more than 6 days.Proof compound glycyrrbizic acid tripotassium, tannic acid, triclosan are to acne, and especially the acne vulgaris effect with inflammation is remarkable.
Embodiment 9
The test of treatment human body skin verruca plana
Through being diagnosed as male 16-60 year 5 people of skin verruca plana, women 16-60 year 3 people, once the external other drug was invalid.Through externally used compound tripotassium glycyrrhetate, tannic acid and the treatment of triclosan disinfectant solution, all verruca plana progressively comes off after case 3-4 days, to normal skin is non-stimulated on every side.6 people that all came off in 5-15 days, 2 people that do not come off more than 15 days.At present, verruca plana needs laser or cold therapy more, does not still have external used medicine on the market identical curative effect is arranged.
Claims (10)
1, the application of the compositions of glycyrrhizic acid or its salt, tannic acid and triclosan in preparation prevention and treatment humans and animals skin and mucosa infection medicine and daily chemical product, it is characterized in that mainly containing the compositions of glycyrrhizic acid or its salt, tannic acid and triclosan, wherein glycyrrhizic acid or its salt are the 1-50 weight portion, tannic acid or its salt are the 1-100 weight portion, and triclosan is the 1-30 weight portion.
2, according to the preparation of claim 1, wherein glycyrrhizic acid or its salt are the 1-30 weight portion, and tannic acid or its salt are the 10-100 weight portion, and triclosan is the 1-10 weight portion.
3, according to claim 1, wherein glycyrrhizic acid or its salt are selected from Radix Glycyrrhizae, and tannic acid is preferably from the Galla Chinensis extract of gallotannic acid or effective dose.
4, the application of the compositions of glycyrrhizic acid or its salt, tannic acid and triclosan in preparation prevention and treatment skin mucosa antibacterial, fungus and viral infection medicine is characterized in that mainly containing the compositions of glycyrrhizic acid or its salt, tannic acid and triclosan.
5, the compositions of glycyrrhizic acid according to claim 1 or its salt, tannic acid and triclosan is used to prepare the purposes of preventing simultaneously and treating humans and animals skin mucosa antibacterial, fungus, viral infection and acne medicine.
6, the compositions of glycyrrhizic acid according to claim 1 or its salt, tannic acid and triclosan is used to prepare the purposes of preventing and treating humans and animals skin mucosa staphylococcus aureus, escherichia coli, bacillus pyocyaneus, Candida albicans, herpesvirus, human papilloma virus infection medicine.
7, the compositions of glycyrrhizic acid according to claim 1 or its salt, tannic acid and triclosan is used to prepare the purposes of prevention and treatment application on human skin acne medicine.
8, the compositions of glycyrrhizic acid according to claim 1 or its salt, tannic acid and triclosan is used to prepare the purposes of the disease medicament that prevention and treatment humans and animals skin mucosa human papillomavirus cause, comprises condyloma acuminatum, verruca plana, vagina, cervicitis and cervical erosion.
9, the compositions of glycyrrhizic acid according to claim 1 or its salt, tannic acid, triclosan, with the application of enepidermic various supplementary product compatibilities in the various preparations of preparation, can be other external preparation that unguentum, gel, lotion, tablet, suppository, membrane, spray and pharmacy can be accepted.
10, the compositions of glycyrrhizic acid according to claim 1 or its salt, tannic acid and triclosan is used to prepare the purposes of daily chemical product, nursing materials, cosmetics, can be toothpaste, fancy soap, medicated soap, napkin, cleansing milk, shampoo, liquid detergent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100279999A CN101301299A (en) | 2007-05-11 | 2007-05-11 | Medicament composition and use thereof in preparing antimicrobial medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100279999A CN101301299A (en) | 2007-05-11 | 2007-05-11 | Medicament composition and use thereof in preparing antimicrobial medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101301299A true CN101301299A (en) | 2008-11-12 |
Family
ID=40111516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007100279999A Pending CN101301299A (en) | 2007-05-11 | 2007-05-11 | Medicament composition and use thereof in preparing antimicrobial medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101301299A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108042558A (en) * | 2017-12-12 | 2018-05-18 | 长沙拜特生物科技研究所有限公司 | Avermectin preparation used for aquiculture and preparation method thereof |
-
2007
- 2007-05-11 CN CNA2007100279999A patent/CN101301299A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108042558A (en) * | 2017-12-12 | 2018-05-18 | 长沙拜特生物科技研究所有限公司 | Avermectin preparation used for aquiculture and preparation method thereof |
| CN108042558B (en) * | 2017-12-12 | 2020-02-07 | 长沙拜特生物科技研究所有限公司 | Abamectin preparation for aquaculture and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101796423B1 (en) | Composition and ladies genital area cleanser composition comprising composition for inducing Antiviral and antibacterial cause vaginitis and method for manufacturing the same | |
| IL189162A (en) | Use of hydroxybenzoic acid ester and its analogues having at least three -oh substituents for the manufacture of a medicament for the prevention and treatment of hpv virus infection | |
| CN102091318B (en) | Toad peptide antibiotics separated from toad maggots and preparation method of antibacterial drugs thereof | |
| CN102973608A (en) | Application of effective part of cockroach extract in preparing drug for inhibiting fungus growth | |
| CN104353058A (en) | PAP (pokeweed antiviral protein) freeze-dried powder compounding agent and preparation method of thereof | |
| CN103157095B (en) | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof | |
| CN112370489A (en) | Antibacterial gel for restoring ecological balance of women and preparation method thereof | |
| CN109276703A (en) | Antiviral protein of plant complexing agent and preparation method thereof | |
| CN101301299A (en) | Medicament composition and use thereof in preparing antimicrobial medicament | |
| CN100428930C (en) | Application of p-hydroxybenzoic acid and its analogs in the preparation of drugs for the prevention and treatment of skin and mucous membrane viral infections | |
| CN102335373A (en) | Chinese medicinal composition for treating upper respiratory tract infection, and preparation method thereof | |
| CN114099632B (en) | A traditional Chinese medicine fermented product and its application in the preparation of medicines for treating fungal infection and skin diseases | |
| CN101708186A (en) | Application of arsenical sulphide, such as realgar and the like, in preparing medicine resisting malignant tumours and application of arsenical sulphide in preparing medicine resisting bacteria | |
| CN1935145A (en) | Pharmaceutical use of sophora alkaloids tanate for preventing and treating skin and mucosa infection | |
| CN109125444A (en) | The new opplication of Lignum et Radix Naucleae extract | |
| CN108785383B (en) | Antibacterial gynecological external medicine composition and preparation method and application thereof | |
| CN101612203B (en) | Traditional Chinese medicine composition used for treating pointed condyloma and application thereof | |
| CN102349935A (en) | Purpose of ginkgolic acid in preparing external preparation for treating venereal disease, gynopathy and perianal disease | |
| CN115554347B (en) | Virus inhibitor and preparation method and application thereof | |
| CN101618051A (en) | Novel medicinal use of active parts of abelmoschus manihot general flavones | |
| CN100438901C (en) | Chinese-medicinal compound preparation for treating acne and its preparation | |
| CN105079230B (en) | A kind of buccal tablet for treating chronic pharyngitis | |
| CN103751105A (en) | Application of ginkgolic acid nanometer liposome in treatment of gynecological diseases and venereal diseases | |
| CN103751230A (en) | Application of gingko extract nanometer liposome in gynecological disease treatment | |
| CN102670811B (en) | External medicament for treating bacterial vaginosis and colpitis mycotica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20081112 |